• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

    4/28/25 4:15:00 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email

    DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET.

    The conference call with management will follow the release of the Company's first quarter 2025 financial results in the pre-market hours on May 7th.

    Conference Call and Webcast Information:

    Access to the live call:

    Go to the investor relations section of the Company's website at www.amarincorp.com

    Dial in within the United States: 888-506-0062

    International dial in: 973-528-0011

    Access Code: 253130

    Access to replay:

    Dial in within the United States: 877-481-4010

    International dial in: 919-882-2331

    Access Code: 52230

    A replay of the call will also be available through the Company's website shortly after the call.

    About Amarin

    Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.

    Availability of Other Information About Amarin

    Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin's investor relations website and may include social media channels. The contents of Amarin's website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

    Amarin Contact Information

    Investor & Media Inquiries:

    Mark Marmur

    Amarin Corporation plc

    [email protected]

    [email protected]



    Primary Logo

    Get the next $AMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Amarin

      JP Morgan resumed coverage of Amarin with a rating of Underweight

      11/20/23 7:16:51 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin downgraded by Jefferies with a new price target

      Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

      10/25/23 6:25:52 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin upgraded by Jefferies with a new price target

      Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

      1/6/23 7:26:32 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    SEC Filings

    See more
    • Amarin Corporation plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

      6/24/25 7:05:28 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Corporation plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

      5/15/25 5:00:11 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amarin Corporation plc

      10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)

      5/7/25 7:05:23 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Berg Aaron bought $102,400 worth of Ordinary Shares (160,000 units at $0.64), increasing direct ownership by 25% to 805,380 units (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      8/5/24 5:30:03 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Holt Patrick bought $15,724 worth of Ordinary Shares (14,426 units at $1.09), increasing direct ownership by 5% to 314,426 units (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      1/24/24 4:31:21 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cohen Paul converted options into 838 units of American Depositary Shares and covered exercise/tax liability with 437 units of American Depositary Shares (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      4/22/25 9:00:12 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sullivan Diane E. converted options into 838 units of American Depositary Shares and covered exercise/tax liability with 437 units of American Depositary Shares (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      4/22/25 9:00:07 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Odysseas Kostas D converted options into 838 units of American Depositary Shares and covered exercise/tax liability with 437 units of American Depositary Shares (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      4/22/25 9:00:09 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

      -- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with Investor Materials Available at AdvancingAmarin.com -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation (NASDAQ:AMRN) today announced that the Company has entered into an exclusive long-term license and supply agreement (the "Agreement") with Recordati S.p.A. ("Recordati") to commercialize VAZKEPA® (icosapent ethyl) across 59 countries, focused in Europe. This Agreement capitalizes on the early-stage success of VAZKEPA in Europe by partn

      6/24/25 7:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Reports First Quarter 2025 Financial Results

      -- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the first quarter of 2025. "As we begin 2025, our first quarter operational and financial performance reflects continued steady execution against our strategy to maximize the glo

      5/7/25 7:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

      -- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. On April 29, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of April 28, 2025 the Company's common stock had maintained an average closing share price of at least $1.00 over th

      4/29/25 4:15:00 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care